Literature DB >> 28121231

Immunogenicity, safety and antibody persistence of a purified vero cell cultured rabies vaccine (Speeda) administered by the Zagreb regimen or Essen regimen in post-exposure subjects.

Nianmin Shi1, Yibin Zhang2, Huizhen Zheng3, Zhenggang Zhu4, Dingming Wang5, Sihai Li6, Yuhua Li7, Liqing Yang1, Junnan Zhang1, Yunhua Bai1, Qiang Lu1, Zheng Zhang1, Fengji Luo1, Chun Yu5, Li Li1.   

Abstract

AIM: To compare the safety, immunogenicity and long-term effect of a purified vero cell cultured rabies vaccine in post-exposure subjects following 2 intramuscular regimens, Zagreb or Essen regimen.
METHODS: Serum samples were collected before vaccination and on days 7, 14, 42, 180 and 365 post vaccination. Solicited adverse events were recorded for 7 d following each vaccine dose, and unsolicited adverse events throughout the entire study period. This study was registered with ClinicalTrials.gov (NCT01821911 and NCT01827917).
RESULTS: No serious adverse events were reported. Although Zagreb regimen had a higher incidence of adverse reactions than Essen regimen at the first and second injection, the incidence was similar at the third and fourth injection between these 2 groups as well. At day 42, 100% subjects developed adequate rabies virus neutralizing antibody concentrations (≥ 0.5IU/ml) for both regimens. At days 180 and 365, the antibody level decreased dramatically, however, the percentage of subjects with adequate antibody concentrations still remained high (above 75% and 50% respectively). None of confirmed rabies virus exposured subjects had rabies one year later, and percentage of subjects with adequate antibody concentrations reached 100% at days 14 and 42.
CONCLUSIONS: Rabies post-exposure prophylaxis vaccination with PVRV following a Zagreb regimen had a similar safety, immunogenicity and long-term effect to the Essen regimen in China.

Entities:  

Keywords:  Immunogenicity; Post-exposure; Protective effect; Rabies vaccine; Safety

Mesh:

Substances:

Year:  2017        PMID: 28121231      PMCID: PMC5489304          DOI: 10.1080/21645515.2017.1279770

Source DB:  PubMed          Journal:  Hum Vaccin Immunother        ISSN: 2164-5515            Impact factor:   3.452


  25 in total

1.  Rabipur: a reliable vaccine for rabies protection.

Authors:  I Vodopija; Z Baklaić; R Vodopija
Journal:  Vaccine       Date:  1999-03-26       Impact factor: 3.641

2.  [Study on the compliance and economic cost of rabies vaccination].

Authors:  Chuan-lin Wang; Xiao-wei Zhang; Yong-xin Yu
Journal:  Zhongguo Yi Miao He Mian Yi       Date:  2010-06

3.  Persistence of rabies antibody 5 years after postexposure prophylaxis with vero cell antirabies vaccine and antibody response to a single booster dose.

Authors:  Xiaowei Zhang; Zhenggang Zhu; Chuanlin Wang
Journal:  Clin Vaccine Immunol       Date:  2011-07-13

4.  One-year study of the 2-1-1 intramuscular postexposure rabies vaccine regimen in 100 severely exposed Thai patients using rabies immune globulin and Vero cell rabies vaccine.

Authors:  S Chutivongse; H Wilde; D B Fishbein; G M Baer; T Hemachudha
Journal:  Vaccine       Date:  1991-08       Impact factor: 3.641

5.  Safety and immunogenicity of two freeze-dried Vero cell rabies vaccines for human use in post-exposure prophylaxis.

Authors:  Ling-yun Wang; Mei-ping Sun; Xue-chun Zhang; Luo-dan Suo; Ruo-hui Xu; Yan-jie Zou; Li-bo Zuo; Hua Qi
Journal:  Vaccine       Date:  2011-02-03       Impact factor: 3.641

6.  The immunogenicity and safety of vaccination with purified Vero cell rabies vaccine (PVRV) in China under a 2-1-1 regimen.

Authors:  Huazhang Liu; Guihua Huang; Qing Tang; Jia Li; Shouchun Cao; Chuanxi Fu; Qing Cao; Beiyan Liu; Huai Pan; Ming Wang
Journal:  Hum Vaccin       Date:  2011-02-01

7.  Promising rabies vaccine for postexposure prophylaxis in developing countries, a purified vero cell vaccine produced in china.

Authors:  Chuanlin Wang; Xiaowei Zhang; Qingkun Song; Kun Tang
Journal:  Clin Vaccine Immunol       Date:  2010-02-10

8.  Use of a reduced (4-dose) vaccine schedule for postexposure prophylaxis to prevent human rabies: recommendations of the advisory committee on immunization practices.

Authors:  Charles E Rupprecht; Deborah Briggs; Catherine M Brown; Richard Franka; Samuel L Katz; Harry D Kerr; Susan M Lett; Robin Levis; Martin I Meltzer; William Schaffner; Paul R Cieslak
Journal:  MMWR Recomm Rep       Date:  2010-03-19

9.  Molecular epidemiology of rabies in Southern People's Republic of China.

Authors:  Xiao Yan Tao; Qing Tang; Hao Li; Zhao Jun Mo; Hong Zhang; Ding Ming Wang; Qiang Zhang; Miao Song; Andres Velasco-Villa; Xianfu Wu; Charles E Rupprecht; Guo-Dong Liang
Journal:  Emerg Infect Dis       Date:  2009-08       Impact factor: 6.883

10.  Rabies trend in China (1990-2007) and post-exposure prophylaxis in the Guangdong province.

Authors:  Han Si; Zhong-Min Guo; Yuan-Tao Hao; Yu-Ge Liu; Ding-Mei Zhang; Shao-Qi Rao; Jia-Hai Lu
Journal:  BMC Infect Dis       Date:  2008-08-21       Impact factor: 3.090

View more
  5 in total

1.  Pre-marketing immunogenicity and safety of a lyophilized purified human diploid cell rabies vaccine produced from microcarrier cultures: a randomized clinical trial.

Authors:  Xingyu Zhou; Xiaohong Wu; Yong Cai; Shouchun Cao; Xiaoping Zhu; Qiang Lv; Huaigong Chen; Leitai Shi; Jia Li; Xinjie Wang; Yuhua Li; Rong Zhou
Journal:  Hum Vaccin Immunother       Date:  2018-12-10       Impact factor: 3.452

2.  Analysis on the risks of severe adverse events in rabies post-exposure prophylaxis and appropriate decision-making procedure.

Authors:  Shichun Huang; Zhenggang Zhu; Li Cai; Zerong Zhu; Man Zhang; Quan Hu; Yuan Fang
Journal:  Hum Vaccin Immunother       Date:  2018-10-26       Impact factor: 3.452

3.  Immunogenicity and safety of purified vero cell-cultured rabies vaccine under Zagreb 2-1-1 or 5-dose Essen regimen in the healthy Chinese subjects: a randomized, double-blind, positive controlled phase 3 clinical trial.

Authors:  Heng Shen; Zhao Wang; Beifang Yang; Kun Cai; Changjun Jiang; Ronghua Xie; Haitao Xiao; Qunhui Ren; Zhengxu Qi; Jinghui Li; Qiong Li; Jianjun Ye; Faxian Zhan
Journal:  Hum Vaccin Immunother       Date:  2020-08-12       Impact factor: 3.452

4.  Safety, immunogenicity of lyophilized purified vero cell cultured rabies vaccine administered in Zagreb and Essen regimen in post-exposure subjects: A post-marketing, parallel control clinical trial.

Authors:  Lei Zhang; Shichun Huang; Li Cai; Zhenggang Zhu; Jian Chen; Sha Lu; Zerong Zhu; Man Zhang; Yuan Fang; Quan Hu
Journal:  Hum Vaccin Immunother       Date:  2021-02-25       Impact factor: 3.452

5.  Long-term immunity and the effect of one or two booster doses with a lyophilized human rabies vaccine (human diploid cells) at 10 years post primary vaccination in China.

Authors:  Jialei Hu; Shiyuan Wang; Rong Zhou; Hui Liu; Xiaohong Gan; Mingwei Wei; Fengcai Zhu; Fanyue Meng; Wenli Hou
Journal:  Hum Vaccin Immunother       Date:  2021-05-04       Impact factor: 3.452

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.